Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases
Detlef Zillikens(University of Lübeck), Fabian Ziller(Vivantes Klinikum), Rüdiger Eming(Philipps University of Marburg), Iakov Shimanovich(University of Lübeck), Michael Hertl(Universitätsklinikum Gießen und Marburg), Gerhard Fierlbeck(Humboldt-Universität zu Berlin), Ocko Kautz, Franz Karlhofer(Medical University of Vienna), Sven Quist(University Hospital Magdeburg), Kurt Derfler(University of Vienna), Enno Schmidt(Carrier (United States)), Silke Hofmann(Helios Universitätsklinikum Wuppertal), Matthias Goebeler(University of Würzburg), Christian Rosé(Klinik und Poliklinik für Hautkrankheiten), Michael Michael(Friedrich-Alexander-Universität Erlangen-Nürnberg), Martin Nitschke(University Hospital Schleswig-Holstein), Stefan Schanz(University of Tübingen), Andreas Opitz(University of Würzburg)
JDDG Journal der Deutschen Dermatologischen Gesellschaft
October 1, 2007
Cited by 64
Related Papers
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|586
Diagnosis and management of pemphigus: Recommendations of an international panel of experts
|Journal of the American Academy of Dermatology|2018|384
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
|Journal of the American Academy of Dermatology|2011|370
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
|Journal of the European Academy of Dermatology and Venereology|2020|332